AR009278A1 - 7alfa-(xi-aminoalquil)-estratrienos sustituidos, preparados farmaceuticos que los contienen y el empleo de los mismos para preparar medicamentos - Google Patents
7alfa-(xi-aminoalquil)-estratrienos sustituidos, preparados farmaceuticos que los contienen y el empleo de los mismos para preparar medicamentosInfo
- Publication number
- AR009278A1 AR009278A1 ARP970103779A ARP970103779A AR009278A1 AR 009278 A1 AR009278 A1 AR 009278A1 AR P970103779 A ARP970103779 A AR P970103779A AR P970103779 A ARP970103779 A AR P970103779A AR 009278 A1 AR009278 A1 AR 009278A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- hydrogen atom
- atom
- residue
- r16beta
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 8
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 4
- 125000004429 atom Chemical group 0.000 abstract 3
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 1
- 125000001893 nitrooxy group Chemical group [O-][N+](=O)O* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- C07J53/004—3 membered carbocyclic rings
- C07J53/008—3 membered carbocyclic rings in position 15/16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/006—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton spiro-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se refiere a nuevos 7alfa-(xi-aminoalquil)-estratrienos sustituidos de formula general (I), en donde: la cadena lateral SK es un resto de formula (II)en la cual m es 4, 5 o 6; n es 0, 1 o 2; x es 0, 1 o 2; A es un átomo de hidrogeno o ungrupo de alquilo (C1-6); B y D son cada cual un átomo dehidrogeno o A y B son juntos un grupo de alquileno -(CH2)p- con p=2, 3, 4 o 5 y D es un átomo de hidrogeno o A y D son juntos un grupo de alquileno -(CH2)q-con q= 2, 3 o 4 y B es un átomo de hidrogeno; y E es un resto de etilo no sustituido o sustituido una a cinco veces con fluor, o el sustituyente terminal-(CH2)1-E de la cadena lateral es un resto de arilo o de heteroarilo eventualmente sustituido, el cual se encuentra unido directamente al átomo deazufre o a través de hasta 3 grupos de metileno; R1 es un átomo de hidrogeno, un resto hidrocarbonado de hasta 8 átomos de carbono o un resto de formulaR1-C(O)-, en el cual R1 es un átomo de hidrogeno o un resto hidrocarbonado de hasta 8 átomos de carbono o un resto de fenilo; R11 es un átomo dehidrogeno, un átomo de halogeno o un grupo de nitrooxi -O-NO2; R14, R15alfa, R15 beta, R16alfa, y R16beta son cada cual un átomo de hidrogeno o R14 y R15alfa son un enlace adicional o un puente de metileno, o R15beta es un grupo de metilo y R15alfa es un átomo de hidrogeno, o R15alfa y R15beta son en cadocaso un grupo de metilo, o R16alfa y R16beta son juntos un puente de metileno, o R16alfa y R16beta es un átomo de halogeno, o R16alfa y R16beta son juntos ungrupo de metilideno y los sutituyentes R14, R15alfa, R15beta, R16alfa y R16 beta restantes son cada cual un átomo de hidrogeno; R17 es un átomo dehidrogeno, un grupo de alquilo (C1-5), un grupo de alquenilo (C2-5), un grupo de alquinilo (C2-6) o un grupo de trifluorometilo en posicion alfa o beta; y
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19635525A DE19635525A1 (de) | 1996-08-20 | 1996-08-20 | 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR009278A1 true AR009278A1 (es) | 2000-04-12 |
Family
ID=7804367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970103779A AR009278A1 (es) | 1996-08-20 | 1997-08-20 | 7alfa-(xi-aminoalquil)-estratrienos sustituidos, preparados farmaceuticos que los contienen y el empleo de los mismos para preparar medicamentos |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP0920441B1 (es) |
| JP (1) | JP2001503024A (es) |
| KR (1) | KR20000068261A (es) |
| CN (1) | CN1231670A (es) |
| AR (1) | AR009278A1 (es) |
| AT (1) | ATE231882T1 (es) |
| AU (1) | AU728843B2 (es) |
| BG (1) | BG62972B1 (es) |
| BR (1) | BR9711328A (es) |
| CA (1) | CA2263708A1 (es) |
| CZ (1) | CZ57999A3 (es) |
| DE (2) | DE19635525A1 (es) |
| DK (1) | DK0920441T3 (es) |
| EA (1) | EA001577B1 (es) |
| EE (1) | EE04021B1 (es) |
| ES (1) | ES2191857T3 (es) |
| HU (1) | HUP9903106A3 (es) |
| IL (1) | IL128601A (es) |
| IS (1) | IS4976A (es) |
| NO (1) | NO315655B1 (es) |
| NZ (1) | NZ334277A (es) |
| PL (1) | PL186309B1 (es) |
| PT (1) | PT920441E (es) |
| SK (1) | SK18899A3 (es) |
| TR (1) | TR199900432T2 (es) |
| TW (1) | TW552267B (es) |
| UA (1) | UA50792C2 (es) |
| WO (1) | WO1998007740A1 (es) |
| ZA (1) | ZA977482B (es) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR015500A1 (es) * | 1997-12-23 | 2001-05-02 | Schering Ag | 11 BETA-HALoGENO-ESTRATRIENOS SUSTITUIDOS EN 7 ALFA, PROCEDIMIENTO PARA ELABORAR PREPARADOS FARMACEUTICOS QUE CONTIENEN TALES 11 BETA-HALOGENO-ESTRATRIENOSSUSTITUIDOS EN 7 ALFA, ASI COMO SU UTILIZACION EN LA ELABORACION DE MEDICAMENTOS. |
| US6503896B1 (en) | 1997-12-24 | 2003-01-07 | Sri International | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
| US6548491B2 (en) | 1997-12-24 | 2003-04-15 | Sri International | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
| US6054446A (en) | 1997-12-24 | 2000-04-25 | Sri International | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
| DE19807791A1 (de) * | 1998-02-19 | 1999-08-26 | Schering Ag | Kombinationspräparat aus Östrogen und Antiöstrogen |
| DE19833786A1 (de) * | 1998-07-18 | 2000-01-20 | Schering Ag | Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
| DE19842123C1 (de) * | 1998-09-05 | 2000-07-13 | Schering Ag | 11beta-Fluor-7alpha-(14,14,15,15,15-pentafluor-6- methyl-10-thia-6-azapentadecyl)estra-1,3,5(10)- trien-3,17beta-diol als kristallines Ansolvat |
| DE19906159A1 (de) * | 1999-02-09 | 2000-08-10 | Schering Ag | 16-Hydroxyestratriene als selektiv wirksame Estrogene |
| JP2003507376A (ja) * | 1999-08-18 | 2003-02-25 | シエーリング アクチエンゲゼルシャフト | 神経活性を示すピペリジンおよびピロリジン誘導体 |
| GB0000313D0 (en) * | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| DE10019171A1 (de) * | 2000-04-07 | 2001-10-18 | Schering Ag | Zusammensetzungen zur Verwendung als Penetrationsverstärker in transdermalen Formulierungen für hoch lipophile Wirkstoffe |
| AU2006202187B2 (en) * | 2001-11-27 | 2008-11-06 | Bayer Schering Pharma Aktiengesellschaft | 17alpah-alkyl-17beta-oxy-estratrienes and intermediate products for their production, uses thereof and pharmaceutical preparations |
| DE10159217A1 (de) * | 2001-11-27 | 2003-06-05 | Schering Ag | 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate |
| US20040242551A1 (en) * | 2003-05-28 | 2004-12-02 | Schering Ag | Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases |
| ATE482966T1 (de) * | 2004-07-27 | 2010-10-15 | Sicor Inc | Verfahren zur herstellung von 7-alpha-alkylierte 19-norsteroide |
| US8017656B2 (en) | 2005-11-22 | 2011-09-13 | Sumitomo Chemical Company, Limited | Organic sulfur compounds and use thereof |
| DE102007023614A1 (de) | 2007-05-21 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Nichtsteroidale Progesteronrezeptor-Modulatoren |
| DE102007049630A1 (de) | 2007-10-11 | 2009-10-29 | Bayer Schering Pharma Aktiengesellschaft | Nichtsteroidale Progesteronrezeptor-Modulatoren |
| JP2009001551A (ja) | 2007-05-18 | 2009-01-08 | Sumitomo Chemical Co Ltd | 有機硫黄化合物及びその有害節足動物防除用途 |
| JP5298631B2 (ja) | 2007-05-18 | 2013-09-25 | 住友化学株式会社 | 有機硫黄化合物及びその有害節足動物防除用途 |
| TW200904329A (en) | 2007-05-18 | 2009-02-01 | Sumitomo Chemical Co | Organic sulfur compound and its use for controlling harmful arthropod |
| DE102007032800A1 (de) | 2007-07-10 | 2009-01-15 | Bayer Schering Pharma Aktiengesellschaft | Nichtsteroidale Progesteronrezeptor-Modulatoren |
| JP5558358B2 (ja) | 2007-10-16 | 2014-07-23 | レプロス セラピューティクス インコーポレイティド | メタボリック症候群用のｔｒａｎｓ−クロミフェン |
| DE102007058747A1 (de) | 2007-12-05 | 2009-06-10 | Bayer Schering Pharma Aktiengesellschaft | Nichtsteroidale Progesteronrezeptor-Modulatoren |
| EP2070941A1 (en) | 2007-12-14 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Stereoselective synthesis of selective estrogen receptor down-regulators |
| EP2070909A1 (de) | 2007-12-15 | 2009-06-17 | Bayer Schering Pharma AG | Nichtsteroidale Progesteronrezeptor-Modulatoren |
| DE102008057230A1 (de) * | 2008-11-11 | 2010-05-12 | Bayer Schering Pharma Aktiengesellschaft | Synergistische pharmazeutische Kombination mit einem Estrogenrezeptorantagonisten und einem Progestin |
| JP5212350B2 (ja) * | 2008-12-24 | 2013-06-19 | 住友化学株式会社 | 含ハロゲン有機硫黄化合物およびその用途 |
| EP2258375A1 (de) | 2009-06-04 | 2010-12-08 | Bayer Schering Pharma Aktiengesellschaft | 17B-alkyl-17alpha-oxy-estratriene |
| DE102009034366A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| DE102009034367A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten |
| DE102009034368A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| DE102009034362A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| DE102009034526A1 (de) | 2009-07-21 | 2011-02-10 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten |
| DE102009034525A1 (de) | 2009-07-21 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| WO2011092127A1 (en) | 2010-01-26 | 2011-08-04 | Bayer Schering Pharma Aktiengesellschaft | 14,17-bridged estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring |
| DE102010007722A1 (de) | 2010-02-10 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Progesteronrezeptorantagonisten |
| DE102010007719A1 (de) | 2010-02-10 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Progesteronrezeptorantagonisten |
| KR20140089402A (ko) | 2010-06-16 | 2014-07-14 | 앙도르쉐르슈 인코포레이티드 | 에스트로겐-관련 질병의 치료 또는 예방 방법 |
| DE102010030538A1 (de) | 2010-06-25 | 2011-12-29 | Bayer Schering Pharma Aktiengesellschaft | 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
| DE102011004899A1 (de) | 2011-03-01 | 2012-09-06 | Bayer Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| AU2012304412A1 (en) | 2011-09-08 | 2014-03-27 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| DE102011087987A1 (de) | 2011-12-08 | 2013-06-13 | Bayer Intellectual Property Gmbh | 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
| JP2015508825A (ja) | 2012-02-29 | 2015-03-23 | レプロス セラピューティクス インコーポレイティド | アンドロゲン欠乏症を治療するための併用療法 |
| DK3461834T3 (da) | 2013-03-13 | 2021-08-23 | Sage Therapeutics Inc | Neuroaktive steroider |
| SI2983671T1 (sl) | 2013-04-11 | 2020-06-30 | Bayer Pharma Aktiengesellschaft | Dozirna oblika antagonista receptorja progesterona |
| US20160060288A1 (en) * | 2013-04-18 | 2016-03-03 | Xi'anlibang Pharmaceutical Technology Co., Ltd. | Ester derivatives of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-estra-1,3,5(10)-triene-3,17beta-diol having anticancer activity and preparation method thereof |
| JP6628745B2 (ja) | 2014-06-18 | 2020-01-15 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびその使用方法 |
| HRP20210526T8 (hr) | 2015-07-06 | 2021-08-20 | Sage Therapeutics, Inc. | Oksisteroli i postupci za njihovu uporabu |
| AU2016352592B2 (en) | 2015-11-10 | 2023-04-27 | Paracrine Therapeutics Ab | Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and an anti estrogen |
| LT3436022T (lt) | 2016-04-01 | 2022-06-27 | Sage Therapeutics, Inc. | Oksisteroliai ir jų panaudojimo būdai |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| MD3481846T2 (ro) | 2016-07-07 | 2021-11-30 | Sage Therapeutics Inc | 24-Hidroxisteroli 11-substituiți pentru utilizare în tratamentul stărilor legate de NMDA |
| ES2935057T3 (es) | 2016-09-30 | 2023-03-01 | Sage Therapeutics Inc | C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA |
| TWI772331B (zh) | 2016-10-18 | 2022-08-01 | 美商賽吉醫療公司 | 氧固醇(oxysterol)及其使用方法 |
| CN115505019B (zh) * | 2022-11-07 | 2024-01-26 | 南宁师范大学 | 7-酰胺取代雌甾类化合物及其制备方法和应用 |
| CN116041412A (zh) * | 2023-01-13 | 2023-05-02 | 香港中文大学（深圳） | 氟维司群衍生物及其制备方法、应用和治疗乳腺癌的药物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8327256D0 (en) * | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| HU208150B (en) * | 1988-10-31 | 1993-08-30 | Endorecherche Inc | Process for producing new estrogen derivatives having steroid hormone inhibitor activity and pharmaceutical compositions comprising such derivatives |
| DE3925507A1 (de) * | 1989-07-28 | 1991-01-31 | Schering Ag | 14,17(alpha)-etheno- und ethanoestratriene, verfahren zur herstellung dieser verbindungen, sowie ihre verwendung zur herstellung von arzneimitteln |
| DE4218743C2 (de) * | 1992-06-04 | 2001-10-25 | Schering Ag | Verfahren zur Herstellung C(7)-substituierter Estra-1,3,5(10)-triene sowie neue Ausgangsprodukte für dieses Verfahren |
-
1996
- 1996-08-20 DE DE19635525A patent/DE19635525A1/de not_active Withdrawn
-
1997
- 1997-08-20 EP EP97943814A patent/EP0920441B1/de not_active Expired - Lifetime
- 1997-08-20 DE DE59709239T patent/DE59709239D1/de not_active Expired - Fee Related
- 1997-08-20 NZ NZ334277A patent/NZ334277A/xx unknown
- 1997-08-20 TW TW086111927A patent/TW552267B/zh active
- 1997-08-20 SK SK188-99A patent/SK18899A3/sk unknown
- 1997-08-20 CN CN97198245A patent/CN1231670A/zh active Pending
- 1997-08-20 CZ CZ99579A patent/CZ57999A3/cs unknown
- 1997-08-20 BR BR9711328A patent/BR9711328A/pt unknown
- 1997-08-20 JP JP10510412A patent/JP2001503024A/ja not_active Ceased
- 1997-08-20 AU AU45520/97A patent/AU728843B2/en not_active Ceased
- 1997-08-20 AR ARP970103779A patent/AR009278A1/es not_active Application Discontinuation
- 1997-08-20 CA CA002263708A patent/CA2263708A1/en not_active Abandoned
- 1997-08-20 HU HU9903106A patent/HUP9903106A3/hu unknown
- 1997-08-20 EA EA199900210A patent/EA001577B1/ru not_active IP Right Cessation
- 1997-08-20 IL IL12860197A patent/IL128601A/xx not_active IP Right Cessation
- 1997-08-20 PT PT97943814T patent/PT920441E/pt unknown
- 1997-08-20 TR TR1999/00432T patent/TR199900432T2/xx unknown
- 1997-08-20 DK DK97943814T patent/DK0920441T3/da active
- 1997-08-20 PL PL97331863A patent/PL186309B1/pl not_active IP Right Cessation
- 1997-08-20 ES ES97943814T patent/ES2191857T3/es not_active Expired - Lifetime
- 1997-08-20 UA UA99031552A patent/UA50792C2/uk unknown
- 1997-08-20 AT AT97943814T patent/ATE231882T1/de not_active IP Right Cessation
- 1997-08-20 KR KR1019997001396A patent/KR20000068261A/ko not_active Ceased
- 1997-08-20 ZA ZA9707482A patent/ZA977482B/xx unknown
- 1997-08-20 WO PCT/EP1997/004517 patent/WO1998007740A1/de not_active Ceased
- 1997-08-20 EE EEP199900075A patent/EE04021B1/xx not_active IP Right Cessation
-
1999
- 1999-02-11 IS IS4976A patent/IS4976A/is unknown
- 1999-02-16 BG BG103185A patent/BG62972B1/bg unknown
- 1999-02-19 NO NO19990793A patent/NO315655B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR009278A1 (es) | 7alfa-(xi-aminoalquil)-estratrienos sustituidos, preparados farmaceuticos que los contienen y el empleo de los mismos para preparar medicamentos | |
| AR005423A1 (es) | Derivados morfinoides condensados con heterociclos (ii), su uso como sustancia terapeutica y para preparar medicamentos, composiciones farmaceuticasque los contienen y procedimiento para preparar dichos derivados. | |
| AR015358A1 (es) | Antagonistas de la endotelina: n-[[2'-[[(4,5-dimetil-3-isoxazolil)amino]sulfonil]-4-(2-oxazolil)[1,1'-bifenil]-2-il]metil]-n,3,3-trimetilbutanamida yn-(4,5-demitil-3-isoxazolil)-2'-[(3,3-dimetil-2-oxo-1-pirrolidinil)metil]-4'-(2-oxazolil)[1,1'-bifenil]-2-sulfonamida y sales de los mismos y las compo | |
| DK1083902T3 (da) | Nye galeniske præparatformer af meloxicam til oral administrering | |
| ATE296619T1 (de) | Feste orale dosierungsform von simethicon | |
| AR042273A1 (es) | Derivados de pirazol, procedimiento para prepararlos y las composiciones farmaceuticas que los contienen | |
| AR004219A1 (es) | Nuevos derivados de quinazolina, procedimientos para su preparacion, composiciones que los contienen y su uso en la preparacion de medicamentos,particularmente en el tratamiento de trastornos inflamatorios | |
| CO5630036A2 (es) | Nuevos derivados indol con afinidad por el receptor 5-ht6 | |
| ITTO20040621A1 (it) | Immunogeno sintetico per la terapia e profilassi dell'abuso di droghe e sostanze psicoattive | |
| ES2104887T3 (es) | Derivados de acridina. | |
| DE60332093D1 (de) | Neues phenylalaninderivat | |
| ES2158284T3 (es) | Metil-fenil-oxazolidinonas quirales. | |
| AR023681A1 (es) | Derivados de tetrahidrobenzazepinas, composiciones farmaceuticas y el uso de los mismos para la manufactura de un medicamento. | |
| EP1109532A4 (en) | Oral micro-emulsion composition of silybin | |
| EA199901102A1 (ru) | Производные азетидинилпропилпиперидина, промежуточные соединения и применение в качестве антагонистов тахикинина | |
| DE60321722D1 (de) | Derivate von aryl-chinazolin/aryl-2amino-phenyl-methanon zurförderung der freisetzung von parathormon | |
| ES2248498T3 (es) | Derivados amidas, sulfonamidas o carbamatos aromaticos de acrilonitrilo y composiciones cosmeticas fotoprotectoras que los contienen. | |
| AR013503A1 (es) | Una combinacion de un inhibidor de la monoamina oxidasa y un antagonista o agonista parcial selectivo de h5-ht(1b), formulacion farmaceutica, usos ymetodo de preparacion | |
| AR015945A1 (es) | Composiciones de spray para el cabello autofobicas | |
| ES2061465T3 (es) | Derivados de oxadiazolilalquilpurina, su preparacion y su aplicacion en productos farmaceuticos. | |
| DK0964863T3 (da) | Oxazolidinoner som 5-HT2A-antagonister | |
| DK1648440T3 (da) | Halvfaste formuleringer til den orale indgivelse af taxoider | |
| IT1313551B1 (it) | Composizioni farmaceutiche disperdibili spontaneamente checontengono un antagonista della sostanza p costituito dalla | |
| AR023300A1 (es) | COMPUESTOS HETEROETINILENADOS, COMPOSICIONES FARMACÉUTICAS Y COSMÉTICAS QUE LOS COMPRENDEN Y UTILIZACIoN COSMÉTICA DE LA COMPOSICIoN COSMÉTICA PARA LA HIGIENE CORPORAL O CAPILAR. | |
| UY27133A1 (es) | 11beta-halogenesteroides, su obtención y uso para la preparación de medicamentos y preparados farmacéuticos que contienen 11 beta-halogenesteroides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |